Reporting Quality of Randomized Controlled Trials for the Treatment of Eczema with Chinese Patent Medicine Based on the CONSORT‐CHM Formulas 2017

Li Ming · Boyang Zhou · Lihong Zhou · Linfeng Li

5 citations0/0 files storedEvidence-based Complementary and Alternative Medicine

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Meta-analysis and systematic reviews Complementary and Alternative Medicine Studies Medical Research and Treatments

Abstract

Objective. Chinese patent medicine (CPM) has been widely used to treat eczema in mainland China for decades. This study aims to investigate circulating CPM for eczema in mainland China and to evaluate the reporting quality of randomized controlled trials (RCTs) of them by using the CONSORT‐CHM formulas 2017 (Consolidated Standards of Reporting Trials for Chinese herbal medicine formulas 2017). Methods. Circulating CPM with the indication for eczema was selected by searching three drug databases and confirmed by contacting the manufacturers. RCTs for the treatment of eczema with CPM were selected in four Chinese literature databases and four English literature databases from their inception to August 31, 2019. The reporting quality of included RCTs was assessed based on the CONSORT‐CHM formulas 2017. A univariate analysis was conducted to identify the factors associated with the reporting quality. Results. A total of 70 circulating CPMs had the indication for eczema. Among them, 21 CPMs with 144 RCTs reached the eligible criteria. The mean overall quality score (OQS) of 144 RCTs was 19.85 ± 2.73, which was much less than the maximum score of 38. Of the 38 items, 12 items were reported in over 70% of the trials, 6 items were reported in 50%–70% of the trials, and 16 items were reported in less than 50% of the trials. Publication after 2015 (P < 0.001) and the first author from a university hospital (P = 0.010) were associated with the better reporting quality. Conclusion. There are a lot of circulating CPMs with the indication for eczema in mainland China, but both the quantity and the reporting quality of RCTs regarding those CPMs are suboptimal. It is necessary that authors and journal editors learn and adhere to the CONSORT‐CHM formulas 2017 to enhance the reporting quality of RCTs for the treatment of eczema with CPM.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 5 citations exist upstream.

References

2010CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials 2010CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials 1996Improving the Quality of Reporting of Randomized Controlled Trials 2012Influence of Reported Study Design Characteristics on Intervention Effect Estimates From Randomized, Controlled Trials 2010The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed 2017CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration 2015Comparison of registered and published outcomes in randomized controlled trials: a systematic review 2010CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials (Chinese version)

Imported from OpenAlex (CC0) — nothing here is generated.